The audit has been successfully completed by the US FDA with ‘no observations' or zero 483's, said the company.

The company added that the product manufactured at the above facility continues to be marketed in the USA.

FDC is a fully integrated research-oriented pharmaceutical company engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs).

The company's consolidated net profit rose 14.2% to Rs 40.75 crore on 19.8% jump in net sales to Rs 409.30 crore in Q3 FY23 over Q3 FY22.